Skip to content
Mardepodect
Mardepodect is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F2023———5
Huntington diseaseD006816G10—3———3
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMARDEPODECT
INNmardepodect
Description
Mardepodect (developmental code name PF-2545920) is a drug which was developed by Pfizer for the treatment of schizophrenia. It acts as a phosphodiesterase inhibitor selective for the PDE10A subtype. The PDE10A enzyme is expressed primarily in the brain, mostly in the striatum, nucleus accumbens and olfactory tubercle, and is thought to be particularly important in regulating the activity of dopamine-sensitive medium spiny neurons in the striatum which are known to be targets of conventional antipsychotic drugs. Older PDE10A inhibitors such as papaverine have been shown to produce antipsychotic effects in animal models, and more potent and selective PDE10A inhibitors are a current area of research for novel antipsychotic drugs which act through a different pathway to conventional dopamine or 5-HT2A antagonist drugs and may have a more favourable side effects profile. Mardepodect is currently one of the furthest advanced PDE10A inhibitors in development and has progressed through to Phase II clinical trials in humans. In 2017, development of mardepodect for the treatment of schizophrenia and Huntington's disease was discontinued.
Classification
Small molecule
Drug classphosphodiesterase 10 (PDE10) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1
Identifiers
PDB—
CAS-ID898562-94-2
RxCUI—
ChEMBL IDCHEMBL562318
ChEBI ID—
PubChem CID11581936
DrugBankDB08387
UNII IDR9Y8EY0G42 (ChemIDplus, GSRS)
Target
Agency Approved
PDE10A
PDE10A
Organism
Homo sapiens
Gene name
PDE10A
Gene synonyms
NCBI Gene ID
10846
Protein name
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
Protein synonyms
3',5' cAMP/cGMP phosphodiesterase, dJ416F21.1 (phosphodiesterase 10A), phosphodiesterase 10A1 (PDE10A1), phosphodiesterase 10A7 (PDE10A7)
Uniprot ID
Q9Y233
Mouse ortholog
Pde10a (23984)
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (Q8CA95)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details